Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.
Feuerstein graduated from Emory University with a bachelor's degree in political science.
Recent Articles By The Author
Amgen's Shameful Silence Covers Up Reasons for FDA Drug Rejection
An Amgen drug to treat secondary hyperparathyroidism was rejected by U.S. regulators Wednesday but the biotech company offered no public explanation for why the drug's marketing application was denied.
Hillary Clinton Blasts Drug Prices, Biotech Stocks Plunge; Yes, It Could Be Happening Again
The Nasdaq Biotechnology Index fell 3.5% heading into Wednesday's close, with the loss triggered by a statement from Clinton's presidential campaign blasting Mylan for 'outrageous' pricing of the EpiPen.
Cyclacel Stock Runs on Momentum Rocket Fueled by 'Dumb & Dumber' Optimism
Shares of biotech micro-cap Cyclacel Pharmaceuticals have doubled in price in the past 10 days. Call it the Lloyd Christmas effect.
Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation
Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.
Biotech Stock Mailbag: Heron, Acadia, Exact Sciences, Sarepta
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.